Affymetrix has launched the GeneAtlas System, which offers a complete personal solution for processing Affymetrix microarrays including stations for fluidics, imaging and hybridization, a computer workstation, and analysis software.
TTP LabTech has validated a new cell colony formation assay on the Acumen eX3 fluorescence microplate cytometer in collaboration with ChemPartner.
Oxford Gene Technology (OGT), provider of clinical genetics and diagnostic solutions to advance molecular medicine, has introduced the CytoSure ISCA UPD 4 x 180k array.
Cetero Research is launching a series of scientific seminars, “An Accelerated Path to Proof-of-Concept in Drug Development,” designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase 1 and 2a clinical trial designs.
Roche NimbleGen announces that Southern California-based genomic services provider Ambry Genetics has officially become a Certified Service Provider for the NimbleGen SeqCap EZ Exome workflow.
Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report. The newly discovered gatekeeper is a protein that determines the fate of damaging cells that mistakenly attack the body's own tissues and lead to autoimmune disorders.
Two opportunistic pathogens that were once thought to be very different have evolved some sexual reproduction and disease-causing habits that are not only similar but also suggest that in the microbial world sex and virulence are closely linked.
The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.
A team of researchers has for the first time identified a gene that is required for memory formation in the common fruit fly. The gene may have similar functions in humans shedding light on neurological disorders such as Alzheimer's disease.
DSM BioSolutions and PolyTherics Limited, an innovator in precision engineering of proteins, announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG IFN ?-2a.
Seaside Therapeutics, Inc. announced positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD).
Immutep S.A. announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90% of metastatic breast carcinoma patients.
Vertex Pharmaceuticals Incorporated announced that 65% of people overall achieved a sustained viral response (viral cure) with a telaprevir-based regimen in the Phase 3 REALIZE study, compared to 17% of people who received pegylated-interferon and ribavirin alone.
A federal jury in New Hampshire has awarded $21 million to a woman blinded and scarred by a prescription drug she took for shoulder pain.
The planned buyout of Trubion Pharmaceuticals Inc. by Emergent BioSolutions Inc. cleared a regulatory hurdle, bringing the deal, potentially worth $135.5 million, closer to closing.